Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil
- PMID: 34139114
- PMCID: PMC8835382
- DOI: 10.47626/2237-6089-2020-0151
Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil
Abstract
Objective: To investigate epidemiological factors related to treatment-resistant schizophrenia (TRS) in Northeast Brazil, a region where data about mental health are still scarce.
Methods: This retrospective cross-sectional study included all patients with schizophrenia currently receiving treatment at the outpatient psychiatric clinic of a tertiary hospital in Northeast Brazil. They were divided into TRS and treatment-responsive groups, and epidemiological characteristics of both groups were compared. A logistic regression model investigated factors related to treatment resistance.
Results: Two hundred and five patients were included, 155 treatment-resistant and 50 treatment-responsive. The TRS group had higher use of benzodiazepines (36.1 vs. 18%, p = 0.017) and antiepileptics (36.8 vs. 8.0%, p < 0.001), antipsychotic polypharmacy (28.6 vs. 8%, p = 0.003) and suicide attempts (35.6 vs. 20%, p = 0.04). Age at onset was younger (19.7±7.3 vs. 24.6±8.6 years, p = 0.001) and CGI was higher in TRS (3.72±1.00 vs. 3.16±1.00, p = 0.001). In logistic regression, being married was a protector (odds ratio [OR] = 0.248, 95% confidence interval [95%CI] 0.091-0.679, p = 0.007) and younger age at onset was a predictor (OR = 1.076, 95%CI 1.034-1.120, p < 0.001) of treatment resistance.
Conclusion: Early onset of disease was associated with more treatment resistance, while being married with less resistance. Clinicians should identify early predictors of resistance in order to reduce unfavorable outcomes.
Keywords: epidemiology; Treatment-resistant schizophrenia; clozapine; psychosis; schizophrenia.
Conflict of interest statement
Alcides Ferreira Rêgo Neto has received fees from Servier, Lundbeck, Pfizer, Boehringer Ingelheim, Eli Lilly, Janssen. No other conflicts of interest declared concerning the publication of this article.
Similar articles
-
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study.Int J Neuropsychopharmacol. 2025 Apr 11;28(4):pyaf011. doi: 10.1093/ijnp/pyaf011. Int J Neuropsychopharmacol. 2025. PMID: 40153592 Free PMC article.
-
Atypical antipsychotics for psychosis in adolescents.Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Cochrane Database Syst Rev. 2013. PMID: 24129841 Free PMC article.
-
Clozapine use in the first two years after first-episode psychosis in a real-world clinical sample.Span J Psychiatry Ment Health. 2025 Apr-Jun;18(2):125-132. doi: 10.1016/j.sjpmh.2024.06.001. Epub 2024 Jun 20. Span J Psychiatry Ment Health. 2025. PMID: 38908404
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Cannabis and schizophrenia.Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Cochrane Database Syst Rev. 2014. PMID: 25314586 Free PMC article.
Cited by
-
A controlled open clinical trial of the positive effect of a physical intervention on quality of life in schizophrenia.Front Psychiatry. 2023 Feb 24;14:1066541. doi: 10.3389/fpsyt.2023.1066541. eCollection 2023. Front Psychiatry. 2023. PMID: 36911140 Free PMC article.
References
-
- 3. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318-78. - PubMed
-
- 4. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63-76. - PubMed
-
- 5. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [Internet]. 2014 Feb 12 [cited 2021 Mar 8]. www.nice.org.uk/guidance/cg178 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical